A Afshar-Oromieh1, I Alberts2, C Sachpekidis2, A Rominger2. 1. Klinik für Nuklearmedizin, Inselspital Bern, Freiburgstraße 18, 3010, Bern, Schweiz. ali.afshar@insel.ch. 2. Klinik für Nuklearmedizin, Inselspital Bern, Freiburgstraße 18, 3010, Bern, Schweiz.
Abstract
BACKGROUND: Since their clinical introduction in 2011, PSMA-PET/CT (PSMA: prostate-specific membrane antigen) as well as PSMA therapy of prostate cancer (PC) have spread rapidly worldwide. OBJECTIVES: To summarize the current knowledge about both PSMA-PET/CT and PSMA therapy of PC. METHODS: The knowledge derived from the literature as well as the authors' experiences were collected in this review. RESULTS: PSMA-PET/CT demonstrates a very high sensitivity and specificity for the detection of recurrent PC as well as for the primary staging of intermediate- and high-risk PC. PSMA therapy shows promising results in third-line treatment for patients with castration-resistant, metastatic PC. CONCLUSIONS: PSMA-PET/CT is meanwhile established as the gold standard for the detection of recurrent PC and is in the process of assuming the same role for primary staging of intermediate- to high-risk PC. PSMA therapy serves as a promising third-line therapy in an increasing number of centers.
BACKGROUND: Since their clinical introduction in 2011, PSMA-PET/CT (PSMA: prostate-specific membrane antigen) as well as PSMA therapy of prostate cancer (PC) have spread rapidly worldwide. OBJECTIVES: To summarize the current knowledge about both PSMA-PET/CT and PSMA therapy of PC. METHODS: The knowledge derived from the literature as well as the authors' experiences were collected in this review. RESULTS:PSMA-PET/CT demonstrates a very high sensitivity and specificity for the detection of recurrent PC as well as for the primary staging of intermediate- and high-risk PC. PSMA therapy shows promising results in third-line treatment for patients with castration-resistant, metastatic PC. CONCLUSIONS:PSMA-PET/CT is meanwhile established as the gold standard for the detection of recurrent PC and is in the process of assuming the same role for primary staging of intermediate- to high-risk PC. PSMA therapy serves as a promising third-line therapy in an increasing number of centers.
Authors: Michael J Evans; Peter M Smith-Jones; John Wongvipat; Vincent Navarro; Sae Kim; Neil H Bander; Steven M Larson; Charles L Sawyers Journal: Proc Natl Acad Sci U S A Date: 2011-05-23 Impact factor: 11.205
Authors: Helle D Zacho; Julie B Nielsen; Ali Afshar-Oromieh; Uwe Haberkorn; Nandita deSouza; Katja De Paepe; Katja Dettmann; Niels C Langkilde; Christian Haarmark; Rune V Fisker; Dennis T Arp; Jesper Carl; Jørgen B Jensen; Lars J Petersen Journal: Eur J Nucl Med Mol Imaging Date: 2018-06-06 Impact factor: 9.236
Authors: Sonya Youngju Park; Claudia Zacharias; Caitlyn Harrison; Richard E Fan; Christian Kunder; Negin Hatami; Frederik Giesel; Pejman Ghanouni; Bruce Daniel; Andreas M Loening; Geoffrey A Sonn; Andrei Iagaru Journal: Radiology Date: 2018-05-22 Impact factor: 11.105
Authors: C Marchal; M Redondo; M Padilla; J Caballero; I Rodrigo; J García; J Quian; D G Boswick Journal: Histol Histopathol Date: 2004-07 Impact factor: 2.303
Authors: Ali Afshar-Oromieh; Eleni Avtzi; Frederik L Giesel; Tim Holland-Letz; Heinz G Linhart; Matthias Eder; Michael Eisenhut; Silvan Boxler; Boris A Hadaschik; Clemens Kratochwil; Wilko Weichert; Klaus Kopka; Jürgen Debus; Uwe Haberkorn Journal: Eur J Nucl Med Mol Imaging Date: 2014-11-20 Impact factor: 9.236